Reify Health, a Boston, MA-based clinical trials optimization software provider, raised $220m in Series C funding.
The round, which brought the valuation to $2.2 billion, was led by Coatue Management, with participation from ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
Led by Ralph Passarella, CEO, Reify Health operates two business entities, StudyTeam and Care Access.
- StudyTeam delivers a technology platform for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen, AstraZeneca, and Eli Lilly and Company, and approximately 4,000 research sites across 65 countries.
- Care Access is a decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers, and communities.
The company intends to use the funds to accelerate growth and expansion of both business entities.
In particular, Care Access will accelerate global operations and foster deep partnerships with clinics and other healthcare organizations. The StudyTeam platform will continue to scale and expand its functionality that enables the numerous stakeholders in decentralized trials to execute the complex logistics required to bring trials to patients anywhere.